Evidence map›Paper›PMID 41976152›Full record

ReviewMolecules (Basel, Switzerland)2026

Biphenyl as a Privileged Structure in Medicinal Chemistry: Advances in Anti-Infective Drug Discovery.

Marilia Oliva Gandi, Rodolfo Rodrigo Florido França, Frederico Silva Castelo-Branco, Nubia Boechat

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Marilia Oliva GandiPrograma de Pós-Graduação em Farmacologia e Química Medicinal, Instituto de Ciências Biomédicas-ICB, Universidade Federal do Rio de Janeiro-UFRJ, Rio de Janeiro 21941-902, Brazil.
Rodolfo Rodrigo Florido FrançaLaboratório de Síntese de Fármacos-LASFAR, Departamento de Síntese de Fármacos e Bioativos-DSFB, Instituto de Tecnologia em Fármacos-Farmanguinhos, Fundação Oswaldo Cruz-Fiocruz, Rio de Janeiro 21041-250, Brazil.ORCID 0000-0001-9069-8016
Frederico Silva Castelo-BrancoLaboratório de Síntese de Fármacos-LASFAR, Departamento de Síntese de Fármacos e Bioativos-DSFB, Instituto de Tecnologia em Fármacos-Farmanguinhos, Fundação Oswaldo Cruz-Fiocruz, Rio de Janeiro 21041-250, Brazil.
Nubia BoechatLaboratório de Síntese de Fármacos-LASFAR, Departamento de Síntese de Fármacos e Bioativos-DSFB, Instituto de Tecnologia em Fármacos-Farmanguinhos, Fundação Oswaldo Cruz-Fiocruz, Rio de Janeiro 21041-250, Brazil.ORCID 0000-0003-0146-2218

Funding

Coordenação de Aperfeicoamento de Pessoal de Nível Superior Code 0001FAPERJ E-26/204.033/2024National Council for Scientific and Technological Development 405464/2023-1National Council for Scientific and Technological Development PROEP 447622/2024-2
6 · The paper itself

Abstract

The discovery of novel anti-infective agents is a continuous challenge in medicinal chemistry, particularly due to the rise in resistant fungal and viral strains. Within this context, the biphenyl subunit has been identified as a highly versatile privileged structure capable of interacting with diverse protein targets via hydrophobic and π-interactions. The purpose of this study is to review the pharmacological potential of biphenyl-based compounds, focusing on their application as anti-infective agents. We comprehensively analyzed recent literature and rational design strategies concerning biphenyl derivatives, examining structure-activity relationships, molecular docking insights, and structural optimizations aimed at enhancing both pharmacodynamics and pharmacokinetics. The reviewed studies demonstrate that incorporating biphenyl moieties yields compounds with potent antifungal and antiviral activities. Specifically, optimized biphenyl derivatives exhibit strong inhibitory effects against resistant Candida strains and crucial viral targets, including mutant variants of the HIV-1 reverse transcriptase and protease enzymes. Furthermore, strategic modifications, such as scaffold hopping and the introduction of specific substituents, successfully mitigated cytotoxicity and improved metabolic stability against cytochrome P450 enzymes. Biphenyl serves as a robust and adaptable scaffold for drug design. Its rational structural optimization provides a viable pathway to overcome drug resistance and develop effective, metabolically stable anti-infective therapeutics.

Indexed as

Anti-Infective AgentsBiphenyl CompoundsDrug DiscoveryAnimalsAntifungal AgentsAntiviral AgentsChemistry, PharmaceuticalHumansMolecular Docking SimulationStructure-Activity RelationshipAntifungal AgentsAnti-Infective AgentsAntiviral AgentsbiphenylBiphenyl Compoundsantibacterialantifungalanti-infectiveantiparasiticantiviralbiphenyldrug discoverymedicinal chemistry

Identifiers

PMID41976152
PMCPMC13074742

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.